Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

The FDA expanded Avastin's approval to include patients with platinum-sensitive ovarian cancer.
TONY HAGEN @oncobiz
PUBLISHED: DECEMBER 07, 2016
Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.
Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval is based on results from two randomized controlled phase 3 studies, GOG-0213 and OCEANS. GOG-0213 demonstrated that adding Avastin to chemotherapy led to a non-statistically significant median overall survival (OS) difference of five months compared with chemotherapy alone (42.6 months vs 37.3 months, respectively; HR, 0.84).

Both studies demonstrated a significant improvement in progression-free survival (PFS). In the GOG-0213 study, median PFS improved by 3.4 months with the addition of Avastin to chemotherapy compared to chemotherapy alone (13.8 months vs 10.4 months, respectively), according to Genentech.

The OCEANS study, which enrolled 484 women, showed a median PFS improvement of four months for Avastin with chemotherapy versus placebo plus chemotherapy (12.4 months vs 8.4 months, respectively). The secondary endpoint of OS did not show statistically significant improvement.

In both trials, the Avastin-containing regimens resulted in higher objective response rates (ORRs). The ORR with Avastin was 78 percent in both studies; for the chemotherapy arms, the ORR was 56 percent in GOG-0213 and 57 percent in OCEANS.

The approval gives women with recurrent platinum-sensitive ovarian cancer a treatment option that is superior to chemotherapy alone, said Sandra Horning, M.D., chief medical officer and head of Global Product Development for Genentech, touting the five-month improvement in OS. Woman are considered to have a platinum-sensitive form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy.

Specifically, the new indication supports the use of Avastin either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, Genentech said.

In November 2014, Avastin was approved in the United States for the treatment of women with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy. Women are considered to have a platinum-resistant form of the disease if a relapse occurs less than six months after the last treatment with a platinum-based chemotherapy.



Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.
x-button
 
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
 
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting GetCureNow.com
x